Search
Telavancin
go.drugbank.com/drugs/DB06402ApprovedInvestigationalTelavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.
Nafarelin
go.drugbank.com/drugs/DB00666ApprovedInvestigationalNafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6.
Atomoxetine
go.drugbank.com/drugs/DB00289ApprovedInvestigational[A178090] Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. … Many contain a blackbox warning stating that CNS stimulants, including methylphenidate-containing products and amphetamines, have a high potential for abuse and dependence.
Products: ATOMOXE 1A PHARMA 10MG, ATOMOXE 1A PHARMA 18MGLeuprolide
go.drugbank.com/drugs/DB00007ApprovedInvestigationalLeuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). … [A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™ by Abbvie Endocrine Inc.
Products: LUPRON ® DEPOT 11.25 MG POLVO LIOFILIOZADO PARA RECONSTITUIR A SUSPENSIÓN INYECTABLEEnoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalEnoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. … Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.
Products: ENOX 10000 ANTI-XA IU/1ML KULLANIMA HAZIR ENJEKTOR, 2 ADET, ENOX 10000 ANTI-XA IU/1ML KULLANIMA HAZIR ENJEKTOR, 20 ADETNirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L33354] 3CL<sup>PRO</sup> is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. … [L33359] In December 2021, the FDA granted an emergency use authorization to Paxlovid, a co-packaged product containing both nirmatrelvir and [ritonavir], for the treatment of certain patients with
Lenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigational[A244170, A244175] Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 inhibition as a monotherapy _in vitro_, little to no cross-resistance with existing antiretroviral
Imlifidase
go.drugbank.com/drugs/DB15258ApprovedInvestigationalChronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large. … to non-self HLA antigens, face additional barriers to transplantation.
Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10296ApprovedInvestigational* serotype 6a individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197). … Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae
Synonyms: Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine, Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigenEfalizumab
go.drugbank.com/drugs/DB00095ApprovedWithdrawnEfalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. … It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797]